Role of MicroRNA in Cancer Development and Treatment—2.0

Message from the Guest Editor

Many researchers around the world have demonstrated that the expression of miRNAs is dysregulated in different tumors. Such dysregulation is caused by multiple mechanisms, and exposure to different carcinogens causes dysregulated epigenetic changes and defects in miRNA biogenesis machinery.

Cancer cells with abnormal miRNA expression evolve the capability to sustain proliferative signaling, evade growth suppressors, resist cell death, activate invasion and metastasis, and induce angiogenesis. Therefore, personalized treatment plans that use cancer biomarkers are increasingly needed to classify patients.

Thanks to high-throughput “omics” approaches such as proteogenomics, epigenomics, metabolomics, it is now possible to discover cancer biomarkers including genes, intracellular or secreted proteins, exosomes, circulating tumor cells, and nucleic acids.

Our aim is to provide rigorous peer review and enable rapid publication of cutting-edge research on the role of microRNA in cancer prevention development and treatment to educate and inspire the scientific community worldwide.

We welcome research articles, review articles, and comprehensive reviews.
Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (Medicine (miscellaneous))